bempegaldesleukin,nivolumab
bms,nektar
['melanoma', 'nivo', 'bempeg', 'pivot io,1']
pivot io 001 trial (bempeg+nivo vs nivo) did not meet its primary endpoint of improving pfs (green curve is the control arm). maybe the higher toxicity and less exposure to drug of experimental arm can influence these results? #esmo22 #melanoma (error shown on prior tweet) 
Medical Oncologist. Melanoma and Skin Tumors. Early phase and phase III clinical trials. Hospital Clínic (Barcelona). Opinions are mine.